SCHEMBL20457599

SCHEMBL20457599

CC1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)Cc1c(I)c(O)c2ncccc2c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.51
▸ KMT2A Q03164 6/20 0.51
▸ TDP1 Q9NUW8 5/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ HIF1A Q16665 5/20 0.51
▸ EPAS1 Q99814 5/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ MAPT P10636 4/20 0.51
▸ RECQL P46063 4/20 0.51
▸ IDO1 P14902 4/20 0.51
▸ CES2 O00748 4/20 0.51
▸ HPGD P15428 4/20 0.51
▸ HSD17B10 Q99714 4/20 0.51
▸ CES1 P23141 3/20 0.51
▸ PTPN6 P29350 3/20 0.51
▸ PTPN11 Q06124 3/20 0.51
▸ CYP3A4 P08684 3/20 0.51
▸ BLM P54132 3/20 0.51
▸ KDM1A O60341 2/20 0.51
▸ THRB P10828 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cryptotanshinone SCHEMBL4126834 0.70 MEN1 (1.00) MEN1KMT2ATDP1ALDH1A1HIF1A
Cryptotanshinone SCHEMBL5940386 0.70 MEN1 (1.00) MEN1KMT2ATDP1ALDH1A1HIF1A
Cryptotanshinone SCHEMBL29387944 0.70 MEN1 (1.00) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL29405831 0.63 MEN1 (0.83) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL13883845 0.61 MEN1 (0.74) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL31426472 0.61 MEN1 (0.65) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL16421122 0.60 MEN1 (0.63) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL8199773 0.60 MEN1 (0.63) MEN1KMT2ATDP1ALDH1A1HIF1A
SCHEMBL31007076 0.60 MEN1 (0.63) MEN1KMT2ATDP1ALDH1A1HIF1A
Dihydrotanshinone I SCHEMBL13049977 0.59 TDP1 (1.00) MEN1KMT2ATDP1ALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10039771-B2 Method for cancer cell reprogramming STC.UNM (US) 2018-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10039771-B2 Method for cancer cell reprogramming CREB1, ATF4, CREBBP MEN1 1482/4885KMT2A 1147/4885TDP1 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback